Niklas Boeder

Dr. Niklas Boeder

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
MWMirjam G. Wild
Mirjam G. Wild
ELEdith Lubos
Edith Lubos
ICIgnacio Cruz-Gonzalez
Ignacio Cruz-Gonzalez
IAIgnacio Amat-Santos
Ignacio Amat-Santos
MAMarco Ancona
Marco Ancona
FPFabien Praz
Fabien Praz
Background: Patients with severe tricuspid regurgitation present late and are often ineligible for surgery or transcatheter repair systems. Transfemoral venous implantation of a bicaval valved stent has been proposed as therapeutic option in selected patients. The aim of this study was to summarize the early procedural and clinical outcomes of the novel TRICENTO system for the treatment of patients with symptomatic severe tricuspid regurgitation. Methods: All consecutive patients treated with the custom-made TRICENTO implant at the participating centers were included in this retrospective multicentre registry. Results: A total of 21 high-risk patients (mean age 76±7 years; 67% female) with severe or higher grade tricuspid regurgitation were analyzed. The majority of the patients were in New York Heart Association class III/IV (95%), had peripheral edema (95%), and previous hospitalization for right heart failure (67%). Technical success was 100%, and there was no case of in-hospital mortality. During follow-up (median 61 days), symptomatic improvement was observed (65% in New York Heart Association class I/II; P <0.001). Computed tomography revealed asymptomatic fractures of the TRICENTO prosthesis in 3 patients. Cardiac magnetic resonance imaging obtained in 7 patients showed a significant decrease (252±65 mm 3 at baseline versus 216±58 mm 3 at follow-up, P =0.006) of right ventricular end-diastolic volume. The overall-survival rate was 76% at 1 year. Conclusions: The present data indicate the feasibility of transfemoral bicaval valved stent implantation for the treatment of severe tricuspid regurgitation. Functional improvement and signs of right ventricular reverse remodeling were observed. Stent fractures did not impair valve function, but require refinement of prosthesis design and careful assessment of eligibility criteria.

5 September 2023 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
FBF. Blachutzik
F. Blachutzik
SMS. Meier
S. Meier
MWM. Weissner
M. Weissner
SSS. Schlattner
S. Schlattner
Tommaso GoriTommaso Gori
Tommaso Gori
TIthe ROTA.shock Investigators
the ROTA.shock Investigators
Background: Severely calcified coronary lesions present a particular challenge for percutaneous coronary intervention.Aims: The aim of this randomized study was to determine whether coronary intravascular lithotripsy (IVL) is non‐inferior to rotational atherectomy (RA) regarding minimal stent area (MSA).Methods: The randomized, prospective non‐inferiority ROTA.shock trial enrolled 70 patients between July 2019 and November 2021. Patients were randomly (1:1) assigned to undergo either IVL or RA before percutaneous coronary intervention of severely calcified coronary lesions. Optical coherence tomography was performed at the end of the procedure for primary endpoint analysis.Results: The primary endpoint MSA was lower but non‐inferior after IVL (mean: 6.10 mm2, 95% confidence interval [95% CI]: 5.32–6.87 mm2) versus RA (6.60 mm2, 95% CI: 5.66–7.54 mm2; difference in MSA: −0.50 mm2, 95% CI: −1.52–0.52 mm2; non‐inferiority margin: −1.60 mm2). Stent expansion was similar (RA: 0.83 ± 0.10 vs. IVL: 0.82 ± 0.11; p = 0.79). There were no significant differences regarding contrast media consumption (RA: 183.1 ± 68.8 vs. IVL: 163.3 ± 55.0 mL; p = 0.47), radiation dose (RA: 7269 ± 11288 vs. IVL: 5010 ± 4140 cGy cm2; p = 0.68), and procedure time (RA: 79.5 ± 34.5 vs. IVL: 66.0 ± 19.4 min; p = 0.18).Conclusion: IVL is non‐inferior regarding MSA and results in a similar stent expansion in a random comparison with RA. Procedure time, contrast volume, and dose‐area product do not differ significantly.

6 March 2018 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
HNHolger Nef
Holger Nef
JWJens Wiebe
Jens Wiebe
NBNiklas Boeder
Niklas Boeder
ODOliver Dörr
Oliver Dörr
TBTimm Bauer
Timm Bauer
CHChristian Hamm
Christian Hamm

1 March 2017 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
NBNiklas Boeder
Niklas Boeder
ODOliver Dörr
Oliver Dörr
JRJohannes Rixe
Johannes Rixe
KWKay Weipert
Kay Weipert
TBTimm Bauer
Timm Bauer
HNHolger M. Nef
Holger M. Nef

5 October 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
MAMakoto Araki
Makoto Araki
TYTaishi Yonetsu
Taishi Yonetsu
OKOsamu Kurihara
Osamu Kurihara
ANAkihiro Nakajima
Akihiro Nakajima
HLHang Lee
Hang Lee
IJIk-Kyung Jang
Ik-Kyung Jang
Background: A recent study reported that the outcome of patients with plaque erosion treated with stenting is poor when the underlying plaque is lipid rich. However, the detailed phenotype of patients with plaque erosion, particularly as related to different age groups, has not been systematically studied. Methods and Results: Patients with acute coronary syndromes caused by plaque erosion were selected from 2 data sets. Demographic, clinical, angiographic, and optical coherence tomography findings of the culprit lesion were compared between 5 age groups. Among 579 erosion patients, male sex and current smoking were less frequent, and hypertension, diabetes, and chronic kidney disease were more frequent in older patients. ST‐segment–elevation myocardial infarction was more frequent in younger patients. Percentage of diameter stenosis on angiogram was greater in older patients. The prevalence of lipid‐rich plaque (27.3% in age <45 years and 49.4% in age ≥75 years, P <0.001), cholesterol crystal (3.9% in age <45 years and 21.8% in age ≥75 years, P =0.027), and calcification (5.5% in age <45 years and 54.0% in age ≥75 years, P <0.001) increased with age. After adjusting risk factors, younger patients were associated with the presence of thrombus, and older patients were associated with greater percentage of diameter stenosis and the presence of lipid‐rich plaque and calcification. Conclusions: The demographic, clinical, angiographic, and plaque phenotypes of patients with plaque erosion distinctly vary depending on age. This may affect the clinical outcome in these patients. Registration: URL: https://www.clinicaltrials.gov . Unique identifiers: NCT03479723, NCT02041650.

17 April 2018 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
ODOliver Dörr
Oliver Dörr
CWClaudia Walther
Claudia Walther
CLChristoph Liebetrau
Christoph Liebetrau
TKTill Keller
Till Keller
HTHannes Tabert
Hannes Tabert
HNHolger Nef
Holger Nef
Background: Specific matrix metalloproteinases (MMP‐2, MMP‐9) and inflammatory biomarkers (hsCRP, IL‐6) were found to be consistently up‐regulated in severe mitral valve regurgitation (MR) and are associated with mortality in heart failure patients. The aim of the present study was to examine the prognostic value of biomarkers of cardiac inflammation and remodeling processes in predicting mortality in patients with MR undergoing percutaneous mitral valve repair (PMVR).Hypothesis: We hypothesize that increased cardiac inflammation and extracellular matrix turnover is predictive for mortality in patients with severe mitral regurgitation undergoing MitraClip.Methods: A total of 210 consecutive patients undergoing PMVR were included. PMVR was performed according to standard clinical practice. Venous blood samples for biomarker analyses were collected prior to and 6 months after PMVR. Physiological parameters, medication use, safety events, and all‐cause mortality were followed over 12 months.Results: PMVR was performed successfully in all patients. Twelve months after PMVR there was an effective reduction in the severity of MR (P < 0.001), and an improvement in New York Heart Association class (P < 0.01) was documented. Elevated inflammatory biomarkers (AUChsCRP: 0.738 [IQR, 0.626–0.849], P = 0.001; AUCIL‐6: 0.811 [IQR, 0.724–0.899], P = 0.001) and biomarkers reflecting cardiac remodeling processes (AUCMMP‐2: 0.723 [IQR, 0.641–0.804], P = 0.001; AUCMMP‐9: 0.618 [IQR, 0.534–0.701], P = 0.01) were predictors of adverse cardiac events and mortality in patients with congestive heart failure undergoing PMVR.Conclusions: The present study is the first to identify biomarkers reflecting inflammation (hsCRP, IL‐6) and cardiac remodeling processes (MMP‐2, MMP‐9) as predictors of mortality in high‐risk patients undergoing PMVR.